N/A N=78 Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM
Diabetes Mellitus, Type II
Primary: Percent Change in Plasma Triglycerides — -2.0; 16.0; -5.0; -5.0 percent change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=235 Type 2 Diabetes Exemplar: A Remote Care Service for North West London
Type 2 Diabetes Mellitus
Primary: % Participants Downloading Huma App — 95; 0 Participants
N/A N=14 The Effect of Hypoxia on Type 2 Diabetes and Weight Loss
Type2 Diabetes
Primary: Δ Mean AUC (Area Under the Curve) Plasma [Glucose] — -17.7; 54.9 mmol.min.L-1
Phase 3 N=46 YH1 in Poorly Controlled Type 2 Diabetes
Type 2 Diabetes
Primary: The Percentage Change in HbA1c Level From Baseline to 12 Weeks — -11.1; 0.0 percentage change
Phase 3 N=699 Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY)
Diabetes Mellitus, Type II
Primary: Treatment Failure (Loss of Glycemic Control) — 120; 90; 109; 112 participants
Phase 3 N=127 Vitamin D for Established Type 2 Diabetes (DDM2)
Type 2 Diabetes
Primary: Disposition Index — 0.023; 0.149 index
N/A N=62 A Comparison Chocolate With and Without High Cocoa Solids in Patients With Type 2 Diabetes in a Randomised Clinical Trial
Diabetes Type 2
Primary: Difference in Insulin Resistance (HOMA) Between Treatments After 12 Weeks of Product Intake — 2.82; 2.21; 2.75 HOMA index
N/A N=52 Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics
Type2 Diabetes
Primary: Program Enrollment Rate (%) — 14 Percentage of participants
N/A N=102 Metformin in Overweight Type 2 Diabetes Mellitus
Obesity · Type 2 Diabetes Mellitus
Primary: Change in Weight From Baseline at 12 Months or More — -8.37 Kg — p=<0.05
N/A N=60 Comparison Effects Of Different Exercise Approaches On Type 2 DM Women
Type 2 Diabetes
Primary: Glycosylated Hemoglobin Change — 6.82; 7.17; 6.80; 6.33 percentage of glycosylated hemoglobin — p=0.830
N/A N=127 Low-carbohydrate Versus Low-fat Breakfast in Type 2 Diabetes
Dietary Habits
Primary: Change From Baseline Hemoglobin A1c at 12 Weeks — -0.3; -0.1 % of HbA1c
N/A N=1,915 Genetics of Diabetes Audit and Research in Tayside Scotland (DOLORisk Dundee)
Diabetic Neuropathic Pain
Primary: Neuropathic Pain — 482; 461; 560 Participants
N/A N=58 Preservation of Beta-cell Function in Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Beta-cell Function - C-peptide AUC (Area Under the Curve) — 2096; 1725 ng*min/mL
N/A N=58 Delish Study: Diabetes Education to Lower Insulin, Sugars, and Hunger
Diabetes Mellitus, Type 2
Primary: Frequency of Eating in Response to Cravings (Primary Mechanistic Outcome) — -20.39; -25.27 % of EMAs with craving related eating
N/A N=64 TRE in Type 2 Diabetes (See Food Study 3)
Type2Diabetes
Primary: Change in Glycemic Measures- HbA1c (12w) — -0.22; -0.25 percentage of glycated hemoglobin
Phase 3 N=369 A Study In Patients With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Median Percent Change From Baseline to Week 6 in LDL-c in FDC and RSG Monotherapy — -39.9; 5.4 Percent change in LDL-c — p=<0.0001
N/A N=1,523 A Study of the Current Medical Practice and Outcomes in the Treatment of Type 2 Diabetes Mellitus in an Office Setting (MK-0431-199)
Type 2 Diabetes Mellitus
Primary: Change From Baseline for Mean Hemoglobin A1c (HbA1C) — 6.9; -0.5 Percent of glycosylated hemoglobin
N/A N=88 Surgery or Lifestyle With Intensive Medical Management in the Treatment of Type 2 Diabetes
Type 2 Diabetes Mellitus · Obesity
Primary: Fasting Plasma Glucose <126 mg/dL and HbA1c < 6.5% at Three Years of Follow-up. — 13; 5; 42; 0 % of patients — p=0.60
N/A N=62 Evaluating a Type 2 Diabetes Prevention Program
Type 2 Diabetes · PreDiabetes
Primary: Body Mass Index (BMI) - Post-Test — 30.3; 28.8 kg/m2
N/A N=176 Cooking for Health
Diabetes Mellitus, Type 2
Primary: Change (From Baseline) in Self-reported Intake (Servings/Day) of Sugar-sweetened Beverages (Measured Using the Nutrition Assessment Shared Resource Food Frequency…
N/A N=27 Effects of Mild Hypoglycaemia on Cognitive Function in Type 2 Diabetes
Diabetes Mellitus, Type II · Hypoglycemia · Cognitive Change
Primary: Psychomotor Speed — 48.7; 56.6 score on a scale
N/A N=2,423 Vitamin D and Type 2 Diabetes Study
Prediabetes · Type 2 Diabetes
Primary: Time to Development of Diabetes — 323; 293 Participants
Phase 4 N=21 U-500R Insulin In Type 2 Diabetes With Severe Insulin Resistance Via Omnipod
Type 2 Diabetes · Insulin Resistance
Primary: Improvement in Glycemic Control as Assessed by Change in Hemoglobin A1c (HbA1c) — -1.23 HbA1c percentage
N/A N=55 Type 2 Diabetes and Exercise Function in Single Leg Exercises
Type 2 Diabetes
Primary: Change in Muscle Oxygen Saturation — -10.7127; -8.9149; -12.471; -8.7883 percentage
N/A N=2,062 Diabetes Prevention Using SMS Technology
Prediabetes
Primary: Number of Participants With Progression to Type 2 Diabetes — 216; 234 Participants
Phase 4 N=611 Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes
Diabetes · Diabetes Mellitus, Type 2
Primary: Change From Baseline in Body Weight — -1.05; -0.56 kg — p=0.132
Phase 2 N=24 Effect of Momordica Charantia Administration on Type 2 Diabetes Mellitus, Insulin Sensitivity and Insulin Secretion
Diabetes Mellitus Type 2
Primary: Total and First Phase of Insulin Secretion (Insulinogenic Index and Stumvoll Index) After 90 Days — 0.41; 0.23; 1135.7; 309.0 index
N/A N=20 To Bathe or Not to Bathe
Diabetes Mellitus, Type 2
Primary: Mean AUC (Area Under the Curve) Plasma [Glucose] — 1677; 1797; 1662 AU
Phase 4 N=413 This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 26 for the Per Protocol (PP) Population — -2.01; -1.75 percent — p=<0.0001
Phase 4 N=318 Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM
Diabetes
Primary: HbA1c Level — 6.9; 6.4 percentage of glycated hemoglobin